Compare Dow Inc (DOW) vs Novavax Inc (NVAX) Price & Performance

DOW trades at $28.80, up 3.71% today, near the analyst low target of $28.00. The stock shows a bullish technical signal despite negative profitability, with ROE at -7.86% and net income margin at -3.13%. Recent earnings have beaten expectations, but revenue declined to $39.97B in 2025. Cash flow improved to $1.69B net in 2025, though operating cash flow remains pressured.

Outlook is mixed: analyst consensus is a hold with a $34.22 price target, implying 19% upside, but weak margins and declining revenue pose risks. The dividend yield offers income support, but investors face headwinds from cyclical chemical demand and high debt levels, with debt-to-asset ratio rising to 29.87% in 2025.

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.